Wenham RM, Calingaert B, Ali S, McClean K, Whitaker R, Bentley R, Lancaster JM, Schildkraut J, Marks J, Berchuck A. Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer. J Soc Gynecol Investig. 2003 Sep 1;10(6):381-7.
Arana A, Castellsague J, Trave F, Perez-Gutthann S, Rothman KJ, Arellano FM. Early estimation of excess risk of serious cutaneous reactions for newly marketed drugs. Poster presented at the 1st International Conference on Therapeutic Risk Management & 19th ICPE International Conference on Pharmacoepidemiology; August 2003. Philadelphia, PA. [abstract] Pharmacoepidemiol Drug Saf. 2003 Aug; 12(S1):165.
Chromy J, Odom DM, Eyerman J, McNeeley M, Hughes A. The effect of interviewer experience on the interview process in the national survey on drug use and health. Poster presented at the Proceedings of the American Statistical Association, Section on Survey Research Methods; August 2003. San Francisco, CA.
Cella D, Natale R, Lynch T T, Lee C, Carbone D, Douillard JY, Kay A, Wolf M, Heyes AE, Ward J. Disease-related symptoms in advanced nsclc as measured by the lung cancer subscale (LCS) of the fact-l questionnaire: clinically meaningful improvement with gefitinib (Iressa, ZD1839). Presented at the American Society of Clinical Oncology; May 2003. Chicago, IL.
Lancaster JM, Wenham RM, Halabi S, Calingaert B, Marks JR, Moorman PG, Bentley RC, Berchuck A, Schildkraut JM. No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina. Cancer Epidemiol Biomarkers Prev. 2003 Mar 1;12(3):226-7.
Justus S, Williams VS, Li L, Gilsenan AW, Fleeman K, Deeter R. African-American subgroup results from an hsv-2 seroprevalence study in suburban primary care physician offices. Poster presented at the ICAAC; 2003.